JP2023548467A5 - - Google Patents
Info
- Publication number
- JP2023548467A5 JP2023548467A5 JP2023526068A JP2023526068A JP2023548467A5 JP 2023548467 A5 JP2023548467 A5 JP 2023548467A5 JP 2023526068 A JP2023526068 A JP 2023526068A JP 2023526068 A JP2023526068 A JP 2023526068A JP 2023548467 A5 JP2023548467 A5 JP 2023548467A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- receptor
- car
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109828P | 2020-11-04 | 2020-11-04 | |
| US63/109,828 | 2020-11-04 | ||
| PCT/US2021/058118 WO2022098914A1 (en) | 2020-11-04 | 2021-11-04 | Engineered ipsc and persistent immune effector cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548467A JP2023548467A (ja) | 2023-11-17 |
| JP2023548467A5 true JP2023548467A5 (https=) | 2024-11-13 |
Family
ID=81457363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526068A Pending JP2023548467A (ja) | 2020-11-04 | 2021-11-04 | 操作されたｉＰＳＣ及び持続性免疫エフェクター細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390337A1 (https=) |
| EP (1) | EP4240831A4 (https=) |
| JP (1) | JP2023548467A (https=) |
| KR (1) | KR20230098649A (https=) |
| CN (1) | CN116406373A (https=) |
| AU (1) | AU2021372975A1 (https=) |
| CA (1) | CA3196545A1 (https=) |
| IL (1) | IL302471A (https=) |
| MX (1) | MX2023005029A (https=) |
| WO (1) | WO2022098914A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| EP4551692A1 (en) * | 2022-07-01 | 2025-05-14 | Fate Therapeutics, Inc. | Enhancing effector cell durability and efficacy in adoptive cell therapies |
| AU2023315762A1 (en) * | 2022-07-25 | 2025-01-30 | Immunitybio, Inc. | Treatment of mhc-i negative tumors with nk and t cells |
| WO2024097800A1 (en) * | 2022-11-01 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2 |
| WO2024097901A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b |
| WO2025064822A2 (en) * | 2023-09-20 | 2025-03-27 | Factor Bioscience Inc. | Cells and methods for engineering cells with persistent transgene expression |
| CN118909951B (zh) * | 2024-07-05 | 2025-05-13 | 青岛华赛伯曼医学细胞生物有限公司 | 连续杀伤能力增强的工程化til细胞及其应用 |
| WO2026025087A1 (en) * | 2024-07-26 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Nucleic acids and engineered cells for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| JP2021505131A (ja) * | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| MX2021006194A (es) * | 2018-12-02 | 2021-06-30 | Fate Therapeutics Inc | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. |
| KR20210139472A (ko) * | 2019-04-11 | 2021-11-22 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 iPSC 및 면역 효과기 세포에서의 CD3 재구성 |
-
2021
- 2021-11-04 AU AU2021372975A patent/AU2021372975A1/en active Pending
- 2021-11-04 CA CA3196545A patent/CA3196545A1/en active Pending
- 2021-11-04 US US18/250,733 patent/US20230390337A1/en active Pending
- 2021-11-04 EP EP21890092.6A patent/EP4240831A4/en active Pending
- 2021-11-04 KR KR1020237018838A patent/KR20230098649A/ko active Pending
- 2021-11-04 IL IL302471A patent/IL302471A/en unknown
- 2021-11-04 MX MX2023005029A patent/MX2023005029A/es unknown
- 2021-11-04 JP JP2023526068A patent/JP2023548467A/ja active Pending
- 2021-11-04 WO PCT/US2021/058118 patent/WO2022098914A1/en not_active Ceased
- 2021-11-04 CN CN202180074553.XA patent/CN116406373A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548467A5 (https=) | ||
| JP2022541441A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| JP2021505131A5 (https=) | ||
| AU2021201679B2 (en) | Transgene genetic tags and methods of use | |
| JP2022510207A5 (https=) | ||
| JP2023548829A5 (https=) | ||
| JP2023549098A5 (https=) | ||
| JP2023505206A5 (https=) | ||
| JP2021519061A5 (https=) | ||
| JP7623020B2 (ja) | 同種異系移植のための操作された免疫細胞 | |
| JP2023530704A5 (https=) | ||
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| JP2023545992A5 (https=) | ||
| JP2024109827A (ja) | Ｎｋ阻害性分子を発現する遺伝子改変免疫細胞とその使用 | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| KR20210126008A (ko) | 세포 면역 치료의 조합 | |
| KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
| KR20230137923A (ko) | 신규한 키메라 항원 수용체 및 이의 용도 | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| JP2024515920A5 (https=) | ||
| JP2025520124A (ja) | キメラアダプターポリペプチドを含む組成物及び方法 | |
| JP2024526237A5 (https=) |